Iovance Biotherapeutics Revises 2026 Revenue Outlook
Iovance Biotherapeutics, Inc. has issued updated full-year 2026 revenue guidance, as detailed in an 8-K filing. This revision provides new financial performance expectations for the company, which could influence investor sentiment and market valuation.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.